Sera Prognostics, Inc. (NASDAQ:SERA)
| Market Cap | 77.59M-36.2% |
| Revenue (ttm) | 70.00K-35.2% |
| Net Income | -33.23M-1.5% |
| EPS | -0.67+21.2% |
| Shares Out | 38.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 588.536 |
| Open | 2.21 |
| Previous Close | 2.07 |
| Day's Range | 2.01 - 2.21 |
| 52-Week Range | 1.56 - 3.95 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | 6.00(+195.33%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About SERA
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$SERA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SERA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SERA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SERA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
SERA Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Consulting and professional fees | $1.64M | 61.65% |
| Other income, net | $867.00K | 32.57% |
| Clinical studies and outside processing | $154.00K | 5.79% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New SERA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SERA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SERA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $1.88M |
| VXFVanguard Extended Market ETF | $806.05K |
| IWCiShares Micro-Cap ETF | $214.54K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $100.00K |
| AVSCAvantis U.S. Small Cap Equity ETF | $11.08K |
| DCORU.S. Core Equity 1 Portfolio ETF Class Shares | $10.46K |
Estimated from each fund’s disclosed top holdings × AUM
SERA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SERA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score